Pn-MAPS30plus

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Immune ResponsePneumonia, Bacterial

24 competitors in Immune Response

#DrugCompanyPhaseTrials

1

Influenza Vaccine

Novartis

Phase 3

22

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

13

Xylocaine

MMEDRx USA, Inc.

Phase 2

24

Flumist

AstraZeneca

Phase 3

25

Decadron

AAspen Global Incorporated

Phase 2

16

INMAZEB

Regeneron

Phase 2

17

Rmenb+omv

Novartis

Phase 3

18

Immunonutrition

SSt. Antonius Hospital

Phase 3

19

Ervebo

AANRS, Emerging Infectious Diseases

Phase 2

110

Rabies Vaccine

Novartis

Preclinical

1Show 8 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immune Response2 trials

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Active, not recruiting·GSK·Phase 1·NCT07105722·127 enrolled

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Not yet recruiting·GSK·Phase 1·NCT07428759·120 enrolled

Pneumonia, Bacterial2 trials

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 To 15 Months of Age Receiving a Single Booster Dose

Recruiting·GSK·Phase 1·NCT07406334·45 enrolled

A Phase 1, Observer-blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

Not yet recruiting·GSK·Phase 1·NCT07406347·60 enrolled

Details

Drug Info

Related News